New Data from PROMMIS Study Highlights the Power of SKY92 in Identifying High-Risk… PR Newswire Dec 7, 2024
MosquitoMate receives first Vector Expedited Review Voucher (VERV) from the US… PR Newswire Dec 7, 2024
Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of… PR Newswire Dec 7, 2024
Blueprint Medicines’ Continued Leadership in Redefining the Standard of Care… PR Newswire Dec 7, 2024
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy… PR Newswire Dec 7, 2024
XRX Investors Have Opportunity to Lead Xerox Holdings Corporation Securities Fraud… PR Newswire Dec 7, 2024
Researchers Report New Opportunities to Improve Quality of Life for People with… PR Newswire Dec 7, 2024
Phase 2 data from the ongoing HIBISCUS study shows promise that investigational… PR Newswire Dec 7, 2024
WOLF INVESTOR DEADLINE: Wolfspeed, Inc. Investors with Substantial Losses Have… PR Newswire Dec 7, 2024
